Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...345346347348349350351352353354355...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. (Pubmed Central) -  Mar 26, 2022   
    This study reveals a high international variability and discrepancy on the use of Pdex treatment across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidence based guidelines on prenatal diagnostics, treatment and follow up of pregnancies at risk for CAH.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Attention for sex in COVID-19 trials: a review of regulatory dossiers. (Pubmed Central) -  Mar 26, 2022   
    There are only small differences in efficacy and safety between men and women which are likely to be of limited clinical relevance. Sex-specific efficacy information can generally be found in the publicly available regulatory documents other than the Summary of Product Characteristics, for which more awareness might be required.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  The Effects of 3-Dimensional Bioprinting Calcium Silicate Cement/Methacrylated Gelatin Scaffold on the Proliferation and Differentiation of Human Dental Pulp Stem Cells. (Pubmed Central) -  Mar 26, 2022   
    Cells were cultured in an osteogenic differentiation medium, which contained a complete medium or α-MEM containing aqueous extracts of the 3D-printd GelMa or MTA-GelMa scaffold with 2% FBS, 10 mM β-glycerophosphate, 50 μg/mL ascorbic acid, and 10 nM dexamethasone; cell viability and differentiation were shown by WST-1 assay, Alizarin Red S staining, and alkaline phosphatase staining...Compared with the control group, the 3D-printed MTA-GelMa scaffold promoted the odontogenic differentiation of hDPSCs. The 3D-printed MTA-GelMa scaffold is suitable for the growth of hDPSCs, and the scaffold extracts can better promote odontoblastic differentiation.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing's Disease: Does Size Matter? (Pubmed Central) -  Mar 26, 2022   
    Mean 24 h urinary free cortisol (5.2 ± 5.4 × ULN vs. 7.8 ± 8.7 × ULN) and serum cortisol following low-dose dexamethasone (372.0 ± 324.5 vs. 487.6 ± 329.8 nmol/L), though higher for macroadenomas, were not significant...Though overall rare, increased awareness is needed for patients with CD with tumor extension in the cavernous or sphenoid sinus, which displays increased biochemical burden, highlighting that extent/location of the adenoma may be more important than size per se. Our systematic review, the first on this topic, highlights differences and similarities with our study.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    LETHARGY AND QUADRAPARESIS AS INITIAL MANIFESTATIONS OF COVID-19 CHILD: CASE REPORT. ([VIRTUAL]) -  Mar 26, 2022 - Abstract #CONy2022CONy_70;    
    She was also given IV gamma globulin 400mg/kg for five days. A marked improvement of his neurological deficit was noted over a period of 16 days after treatment In the current pandemic Status; COVID-19 should be considered a differential diagnosis in patients presenting with loss of consciousness, ataxia, convulsions, motor deficits, encephalitis, myelitis, or Neuritis.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Darzalex (daratumumab) / J&J
    Disease mechanisms & biomarkers ([VIRTUAL]) -  Mar 26, 2022 - Abstract #EMN2022EMN_81;    
    On the other hand, gain1q21 is associated to a dismal outcome after first-line melphalan and dexamethasone or after lenalidomide or daratumumab-based regimens in relapsed/refractory disease...Finally, it is under investigation the possible additional prognostic role of advanced cardiac imaging at diagnosis and after treatment. Clinical observation assisted by biomarkers and advanced imaging will improve our knowledge of the mechanisms of disease in cardiac amyloidosis, giving a better perspective of the role of organ toxicity and amyloid load.
  • ||||||||||  What to do first ([VIRTUAL]) -  Mar 26, 2022 - Abstract #EMN2022EMN_59;    
    Of note, venetoclax-dexamethasone alone or in combination will be reserved for patients with t(11;14)...There are some other combination recommended for third line and beyond, and based on pomalidomide-dexamethasone, if the patient has not been previously exposed, in combination with either isatuximab or elotuzumab although it is also possible to combine with cyclophosphamide. In summary, we have to follow the current guidelines for the management of MM at first relapse although the treatment landscape is rapidy evolving and phase 3 trials are ongoing with the objective of incorporating the BCMA-targeted therapy at first relapse.
  • ||||||||||  Extramedullary disease ([VIRTUAL]) -  Mar 26, 2022 - Abstract #EMN2022EMN_38;    
    Currently the unmet need for treatment of high risk myeloma including patients presenting with EMD is still unanswered. Based on experience among advanced patients are promising and novel immunotherapeutic approaches integrated into the induction may provide a breakthrough in this area(4,12).
  • ||||||||||  Genetic evolution: Druggable MM therapeutics: Pathogenetic pathways ([VIRTUAL]) -  Mar 26, 2022 - Abstract #EMN2022EMN_26;    
    Another important target is the E3 ubiquitin ligase CRBN, and in fact, two CELMoDs (CRBN modulators), Iberdomide (CC-220) and CC-92480, have demonstrated activity (ORR 30-50%) and a favorable safety profile in heavily pretreated patients...Other approaches are also attractive such as myc inhibition or additional ways of activating the immune system. In this last field, two novel mechanisms hold significant promise: inhibition of the do not eat me signal with anti-CD47 MoAb such as Magrolimab, or the use of Modakafusp a CD38 MoAb with two IFN attenuated molecules that induces a anti-tumoral One important field of investigation is the search for biomarkers predicting sensitivity or resistance to a given agents, such as venetoclax in t(11;14) patients, Mcl-1 inhibitors in patients with 1q+, or RAS/RAF/MEK inhibitors for patients with activation of this pathway.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Central and peripheral effects of environmental enrichment in a mouse model of arthritis. (Pubmed Central) -  Mar 25, 2022   
    Finally, EE induced a marked increment of brain-derived nerve factor (BDNF) expression in the hippocampus, an effect that was fully prevented by dexamethasone. These data bring novel evidence on the peripheral and central effects of EE in a mouse arthritis model.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Retrospective data, Journal:  Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis. (Pubmed Central) -  Mar 25, 2022   
    The IMC regimen comprised triamcinolone acetonide 20-40 mg/mL injected every 4-6 weeks...This study demonstrated the efficacy and safety of IMC in the treatment of severe or active AA; however, the relapse rate remained relatively high after discontinuation of the therapy. Nail involvement was a negative predictor of significant hair regrowth, while disease duration longer than 6 months predicted AA relapse.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Journal:  Acute Vulvar Aphthous Ulceration After COVID-19 Vaccination: 3 Cases. (Pubmed Central) -  Mar 25, 2022   
    Clinicians should be aware of the possible risk of vulvar aphthosis after COVID-19 vaccine administration. Nevertheless, its occurrence should not prevent affected patients from receiving future doses of COVID-19 vaccines, as the mortality and morbidity of COVID-19 infection significantly outweigh the risk of vulvar aphthosis recurrence.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Cyclic Polypeptide D7 Protects Bone Marrow Mesenchymal Cells and Promotes Chondrogenesis during Osteonecrosis of the Femoral Head via Growth Differentiation Factor 15-Mediated Redox Signaling. (Pubmed Central) -  Mar 25, 2022   
    Then, we applied D7 treatment to steroid-induced ONFH (SONFH) in an in vitro model produced by dexamethasone (DEX) to further elucidate the underlying mechanisms...In addition, DEX-induced excessive reactive oxygen species (ROS) generation was an upstream trigger of GDF15-mediated signaling, and D7 ameliorated this DEX-induced redox imbalance by restoring the expression of antioxidants, including superoxide dismutase (SOD) 1, SOD2, and catalase, via regulation of GDF15 expression. In conclusion, our findings revealed the potential therapeutic effects of D7 in SONFH and showed that this protective function may be mediated via inhibition of DEX-induced ROS and activation of GDF15/AKT/mTOR signaling, thereby providing insights into the potential applications of D7 in SONFH treatment.
  • ||||||||||  dexamethasone / Generic mfg.
    COVID-19 INFECTION IN LIVER TRANSPLANT RECIPIENTS: CLINICAL FEATURES, HOSPITALIZATION, AND MORTALITY FROM A CANADIAN MULTICENTRE COHORT ([VIRTUAL]) -  Mar 25, 2022 - Abstract #CDDW2022CDDW_224;    
    The majority of patients (92%) were on tacrolimus monotherapy or a combination of tacrolimus and mycophenolate mofetil (MMF); median tacrolimus level at COVID-19 diagnosis was 5.3 ug/L (4.0, 8.1)...Eighteen patients (37%) required hospitalization, 6 (12%) were treated with dexamethasone, and 3 (6%) required ICU admission and mechanical ventilation...Of note, the median tacrolimus levels were much lower in comparison to the target of 8–10 ug/L used in the first year post-transplant. As the landscape of COVID-19 changes with vaccination, evolving treatments, and increasing rates of variant transmission, additional studies are required to continue identifying trends in clinical outcomes.
  • ||||||||||  dexamethasone / Generic mfg.
    EVALUATING GLYCOCAGED DEXAMETHASONE IN SHIP-DEFICIENT MICE ([VIRTUAL]) -  Mar 25, 2022 - Abstract #CDDW2022CDDW_38;    
    Additionally, the mean IL-1β concentration in tissue homogenates of mice treated with the molar equivalent of 1 mg/kg caged DEX was reducedConclusions SHIP-/- mice express decaging activity are effectively treated by DEX, and caged DEX shows similar efficacy at reducing SHIP-/- ileal pathology at lower concentrations than uncaged DEX. In future experiments, we will examine caged DEX at a lower concentration, and in 2nd mouse model of intestinal inflammation.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg.
    Trial completion date:  Maintenance Therapy With Subcutaneous Bortezomib (clinicaltrials.gov) -  Mar 25, 2022   
    P2,  N=63, Active, not recruiting, 
    In future experiments, we will examine caged DEX at a lower concentration, and in 2nd mouse model of intestinal inflammation. Trial completion date: Nov 2021 --> Nov 2022